Literatur
-
1 Adult Treatment Panel III Report .National Cholesterol Education Program. Available at: http://www nhlbi nih gov/guidelines/cholesterol/atp3_rpt htm 2001
-
2
LaRosa J C.
Lipoproteins and CAD risk in women.
J Myocardial Ischemia.
1991;
3
35-42
-
3
Bittner V, Tripputi M, Hsia J, Gupta H, Steffes M.
Remnant-like lipoproteins, hormone therapy, and angiographic and clinical outcomes: the Women’s Angiographic Vitamin & Estrogen trial.
Am Heart J.
2004;
148
293-299
-
4
Shai I, Rimm E B, Hankinson S E. et al .
Lipoprotein (a) and coronary heart disease among women: beyond a cholesterol carrier?.
European Heart Journal.
2005;
26
1633-1639
-
5
LaRosa J C, He J, Vupputuri S.
Effectof statins on risk of coronary disease: a meta-analysis of randomized controlled trials.
JAMA.
1999;
282
2340-2346
-
6
Heart Protection Study Collaborative Group .
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial.
Lancet.
2002;
360
7-22
-
7
The Treating to New Targets (TNT) Investigators .
Intensive lipid lowering with atorvastatin in patients with stable coronary disease.
N Engl J Med.
2005;
352
1425-1435
-
8
The Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators .
Intensive versus moderate lipid lowering with statins after acute coronary syndromes.
N Engl J Med.
2004;
350
1495-1504
-
9
Walsh J ME, Pignone M.
Drug treatment of hyperlipidemia in women.
JAMA.
2004;
291
2243-2252
-
10
The CARDS Investigators .
Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the collaborative Atorvastatin diabetes Study (CARDS): multicentre randomized placebo controlled trial.
Lancet.
2004;
354
685-696
Prof. Dr. I. Gouni-Berthold
Klinik II und Poliklinik für Innere Medizin der Universität zu Köln
Kerpener-Straße 62
50937 Köln
Phone: 0221 478-4088
Fax: 0221 478-4179
Email: ioanna.berthold@uni-koeln.de
